Latest New Zealand Market News

Multistack International Limited (ASX:MSI) has agreed in principle to sell all its assets and liabilities to Hong Kong-based Willing Y Limited, marking a significant strategic shift as MSI plans to discontinue its current business and explore new opportunities.

Channel Infrastructure is partnering with the New Zealand Government to rapidly expand diesel storage capacity at Marsden Point, aiming to strengthen fuel supply resilience within two months.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.

Yojee Limited reported a 9% revenue increase driven by software activities, while net losses widened due to accelerated investment in its MOSAIC platform and joint venture costs. The company maintains a robust cash balance and has strengthened its leadership ahead of a mid-2026 commercial launch.

Inghams Group reports flat revenue but a sharp 42% drop in EBITDA for the first half of FY26, revising full-year earnings guidance lower amid ongoing cost inflation and operational challenges.

Harmoney Corp Limited reported a striking 166% rise in Cash NPAT to $6.1 million for the half-year ended December 2025, driven by robust loan originations and improved interest margins. The company’s scalable model and refinancing efforts underpin its strong financial momentum.

Solvar Limited reported a 5.8% rise in half-year NPAT to $20 million, driven by the sale of its New Zealand written-off loan book and expanded debt facilities. The company also announced a special dividend and outlined growth plans in commercial lending.

Ventia Services Group has extended its contract with Transpower New Zealand to continue delivering specialist electrical services across the national grid, locking in NZ$160 million in revenue through 2029.

Baby Bunting has reported record half-year sales and margin growth for 1H FY26, underpinned by its Store of the Future refurbishments and strategic expansions. The company maintains its full-year profit guidance while unveiling a new exclusive partnership with premium brand Stokke.

Temple & Webster Group Limited reported a robust 20% revenue increase to $376 million in the first half of FY26, maintaining momentum towards its $1 billion revenue target by FY28. The company’s strategic investments in AI, exclusive products, and new markets like New Zealand underpin its expanding market presence.

Temple & Webster reported a 20% revenue increase to $375.9 million for H1 FY26, driven by record active customers and exclusive product growth. However, profit before tax fell 25% to $9.4 million, impacted by investments in New Zealand and higher marketing spend.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.